Skip to content
Invitrocue - Transforming bioanalytics
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Customized Assays and Disease Modelling
    • Invivocue – Humanized Mice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Customized Assays and Disease Modelling
    • Invivocue – Humanized Mice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)

Proposed Issue of Securities

December 7, 2017

Proposed Issue of Securities
proposed issues of securities proposed issues of securities dec 2017

Categories ASX Announcements
Post navigation
Results of Annual General Meeting
Appendix 3B

Recent Posts

  • Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean
  • Invitrocue’s Onco-PDO test is Singapore’s and world’s first validated and approved Clinical Cancer Drug Screening service for Personalised Oncology
  • Operational Updates – February 2024
  • Operational Updates – October 2023
  • Thailand FDA grants approval for commercial use of MyTruHealth and MyTruAge DNA Methylation Test Kit

GET IN TOUCH

51 Science Park Road, #01-11/13 The Aries, Singapore Science Park II Singapore 117586

GENERAL / PHARMACOLOGY ENQUIRIES:

+65 6460 0497
contact@invitrocue.com

ONCO-PDO ENQUIRIES:

+65 6819 0181
onco-pdo@invitrocue.com
SAC - SINGLAS Accredited Laboratory

SERVICES

Home
About Us
Oncology
Preclinical Services
Investors
News & Resources
Contact Us

Logo Invitrocue
Icon-twitter-x Facebook-f Linkedin-in Youtube

© Copyright 2025 Invitrocue. All rights reserved
Impressum | Privacy Policy | Cookies Policy | Cookie Settings